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Aims: Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or
type 2 diabetes mellitus (T2DM).
Methods: Data from US physician electronic health records (Humedica®) from 2009–2011 were utilized.
Patients were deﬁned as having above–target glycemic control if they had an HbA1c ≥7% at any time during
the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients,
and examined associations between BMI categories and probability of having above–target glycemic control
(≥7% and b8%, ≥8% and b9%, or ≥9%) while controlling for patient demographics, general health, comorbid
conditions, and antihyperglycemic medication use.
Results: There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese
(BMI ≥30 kg/m2). For T1DM, being overweight (BMI 25– b 30), obese class I (30– b 35), II (35– b 40), or III
(≥40) was associated with a signiﬁcantly higher probability of having HbA1c ≥ 8% and b9% or ≥9%, while
being overweight was associated with a signiﬁcantly higher probability of having HbA1c ≥7% and b8%
compared to normal BMI (BMI ≥ 18.5 and b 25). For T2DM patients, being overweight, obese class I, II, or III
was associated with a signiﬁcantly higher probability of having HbA1c ≥7% and b8%, ≥8% and b9%, or ≥9%.
Conclusions: For both T1DMandT2DMpatients, therewere positive and statistically signiﬁcant associations between
being overweight or obese and having suboptimal glycemic control. Theseﬁndings quantify the associations between
obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.lson co
compe
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus currently affects 29.1 million Americans
(Centers for Disease Control and Prevention, 2014b) and the United
States (US) economywith $245 billion (2012) in treatment costs each
year (American Diabetes Association, 2013). Obesity is also highly
prevalent in the US, with more than one-third of the adult populationmpleted this work as
nsated by Eli Lilly and
metrics.com (MJ. Lage),
elson),
an open access article under tclassiﬁed as obese, indicated by a body mass index (BMI kg/m2) of 30
or above (Centers for Disease Control and Prevention, 2014a). Being
overweight or obese independently increases the risks of developing a
large number of serious illnesses, including coronary heart disease,
some cancers, stroke, liver and gallbladder disease, and osteoarthritis
(Centers for Disease Control and Prevention, 2013; Hubert, Feinleib,
McNamara, & Castelli, 1983; National Institutes of Health and National
Heart, Lung, and Blood Institute, 1998). Because of these obesity-
associated conditions, obese Americans have 42% higher yearly health
care costs relative to those of normal weight, and the aggregate costs
of obesity in the US have been estimated at $147 billion (2008 dollars)
annually, or 9.1% of all medical spending (Finkelstein, Fiebelkorn, &
Wang, 2003). The prevalence of obesity in the US has risen
signiﬁcantly over the past several decades (Centers for Disease
Control and Prevention, 2014a) and has been a major driver of the
nation's rapidly increasing health care costs (Finkelstein et al., 2003).
Excess body weight has been identiﬁed as an issue of concern for
both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitushe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Inclusion/Exclusion criteria and sample size.
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and 80% of individuals with T2DM are overweight or obese (National
Institutes of Health and National Institute of Diabetes and Digestive
and Kidney Disease, 2004). Among patients with T2DM, obesity raises
the odds of developing many common diabetic complications,
including heart disease, retinopathy, dyslipidemia, and hypertension
(American Diabetes Association, 2014). Previous studies have shown
that the glycemic control of patients with T2DM tends to worsen with
weight gain and to improve with weight loss, (Neiberg et al., 2012;
Shantha, Kumar, Kahan, & Cheskin, 2012) while signiﬁcant weight
loss, such as that associated with gastric bypass surgery, has been
shown to lead to a partial or total remission of T2DM (Scopinaro et al.,
2014). Among individuals with T1DM, research has shown a 7-fold
increase in the prevalence of obesity among patients with T1DM after
18-years follow up, with the amount of insulin used positively
associated with weight gain (Conway et al., 2010). Furthermore,
clinical trial evidence shows that weight gain among patients with
T1DM is associated with an increased cardiovascular risk (Purnell et
al., 1998) and that this risk is lower among patients with improved
glycemic control (Williams, Erbey, Becker, & Orchard, 1999).
In addition to the research which has examined the relationship
between glycemic control and changes inweight, there has been some
research which has focused on the relationship between BMI
categories and glycemic control. For example, a study using data
from the National Health and Nutrition Examination Survey
(NHANES) between 1999 and 2006 showed that mean HbA1c levels
were highest for diabetes patients with BMI b 25 (Nguyen, Nguyen,
Lane, & Wang, 2011). However, little research has focused on the
relationship between BMI classiﬁcations and HbA1c among a large,
insured population.
The goal of this research was to improve understanding of the
association between obesity and glycemic control. Speciﬁcally, the
analyses used a large, cross-national population of individuals with
T1DM and T2DM to examine the association between BMI classes and
the odds of having suboptimal glycemic control, as indicated by a
hemoglobin A1c (HbA1c) value higher than b7%, given that such a
target has been deﬁned as reasonable for many non-pregnant adults
(American Diabetes Association, 2014). Furthermore, the analyses
examines a range of above target glycemic control (HbA1c ≥7% and
b8%, ≥8% and b9%, and ≥9%) and also identiﬁes other factors linked to
suboptimal glycemic control.
2. Methods
An electronic health record (EHR) data base (Humedica®) was
analyzed. The data were extracted from various health information
technology systems in medical group practices and integrated
delivery networks (IDNs), and contain laboratory results, radiology
and pathology reports, physician and nurse notes, prescriptions
written and dispensed, procedures, diagnoses, and other details of a
patient's ofﬁce visit. Humedica data are based upon a network of
provider organizations that treat approximately 30 million patients
who may be uninsured or insured via commercial insurance,
Medicare, or Medicaid. The data come from 38 states, although the
midwestern region of the US is overrepresented. The data are all
de-identiﬁed and fully comply with Health Insurance Portability and
Accountability Act (HIPAA) regulations.
To be included in this study, an individual was ﬁrst identiﬁed as
having T1DM or T2DM between January 1, 2009 and December 31,
2011. Patients were classiﬁed as having T1DM if they received at least
two diagnoses of T1DM (250.x1 or 250.x3) during the study period
and were classiﬁed as having T2DM if they received at least two
diagnoses of T2DM (250.x0 or 250.x2) and were not in the T1DM
cohort. Individuals were also required to have at least one BMI value
and one HbA1c value recorded during this time period, and to be at
least age 18 years in the year 2009. Individuals were excluded if theywere diagnosed as pregnant at any time in the 3-year time period or
if their ﬁrst active record was after January 2009 or their last active
record was before December 2011. Finally, patients identiﬁed as
underweight were excluded since they represented less than 1% of
the patients. These inclusion/exclusion criteria resulted in a
sample size of 259,595 (248,567 with T2DM and 14,028 with
T1DM). Fig. 1 illustrates how each inclusion/exclusion criterion
affected sample size.
Descriptive statistics (mean and standard deviation or medians
and interquartile ranges for continuous variables, and frequency and
percentages for categorical variables) were used to characterize the
sample. Student's t-tests and chi-square tests were used to assess
differences between cohorts based upon glycemic control. Glycemic
control was measured as the highest recorded HbA1c over the study
period and patients were categorized into four groups depending
upon whether their HbA1c was b7%, ≥7% and b8%, ≥8% and b9%, or
≥9%. These cutoffs were based upon clinical guidelines which
recommend a treatment target of HbA1c b7% for many non-pregnant
adults with diabetes and suggest that a target of b8% may be
appropriate for patients with a history of severe hypoglycemia,
limited life expectancy, or diabetic complications or comorbidities
(American Diabetes Association, 2015). Furthermore, results from
an observational study among the elderly suggest that a target
HbA1c of 8 to 8.9% may be appropriate (Yau et al., 2012) and that
an HbA1c value of N 9% is associated with increased mortality risk
among patients with type 2 diabetes (Nicholas, Charlton, Dregan, &
Gulliford, 2013).
Multinomial logistic regressions were then estimated in order to
examine the relationship between glycemic control and BMI (kg/m2)
levels (normal - 18.5 to b25, overweight - 25 to b30, obesity I - 30 to
b35, obesity II - 35 to b40, and obesity III - ≥40) (World Health
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person-level characteristics, general health, comorbidities, complica-
tions, and antihyperglycemic medication use. Characteristics of
interest included age, sex, race, and region of residence. In addition,
this study included the percentage of college graduates within the
3-level zip code of patient residence as a proxy for socioeconomic
status. General health was proxied by the Charlson Comorbidity Index
(CCI) which is constructed by weighting 17 different conditions
including peripheral vascular disease, congestive heart failure and
malignancy (Quan et al., 2005). Comorbidities and complications
were identiﬁed by ICD 9 codes and included the following: diabetic
retinopathy (362.01; 362.02; 362.10; 379.23; 250.5x), diabetic
neuropathy (357.2 or 250.6x), diabetic nephropathy (250.4x),
ischemic heart disease (410.xx–413.xx), stroke (430.xx–434.xx and
436.xx), dyslipidemia (272.0–272.4), chronic kidney disease (CKD)
(585.xx), hypertension (401.xx–405.xx), smoking (305.1 or V15.82),
anxiety (300.xx except 300.3 and 300.4), and depression (311; 296.2;
296.3; 296.5–296.7; 300.4 or 296.82; 296.89). Regression analyses
were conducted separately for the T1DM and T2DM cohorts.
As a test of the sensitivity of these ﬁndings, the analyses were
conducted with glycemic control deﬁned based upon mean HbA1c
over the course of the study period rather than highest HbA1c. While
use of the highest HbA1c when constructing cutoffs allows for an
examination based upon always being at target HbA1c, the use of
mean values examines results based upon a less rigorous standard of
achieving target HbA1c on average, although HbA1c could be above
target for a substantial time period. All analyses were conducted using
SAS, version 9.3 (SAS Institute, Cary, NC). A two-tailed p-value b0.05
was considered, a priori, to be statistically signiﬁcant.
3. Results
Fig. 2 shows there are statistically signiﬁcant differences between
the T1DM and T2DM cohorts, with individuals in the T1DM group
more likely to be identiﬁed as normal weight (BMI ≥18.5 and b25),
while T2DM were more likely to be classiﬁed as obese I, obese II, or
obese III. Speciﬁcally, 47.8% of the T1DM cohort, as compared to 63.4%
of the T2DM cohort, was identiﬁed as obese.
Tables 1A and 1B present the descriptive statistics for T1DM and
T2DM groups, respectively. Results are reported both for the entire
cohort and by subgroups deﬁned according highest recorded HbA1c
during the 3 years studied. For the cohorts as a whole, results revealed
that the largest percentages of T1DM individuals were residents of theFig. 2. Weight categorizatimidwest (40.0%) and 50.6% were male, while in the T2DM cohort,
most individuals were residents of the south (42.4%) and 49.1% were
male. The median age was 56 years in the T1DM cohort and 64 in the
T2DM cohort. In both cohorts, most patients were Caucasian (64.5%
for T1DM and 66.5% for T2DM). The most commonly diagnosed
comorbidities were dyslipidemia (77.9% for T1DM and 85.8% for
T2DM) and hypertension (73.0% for T1DM and 84.6% for T2DM) in
both cohorts. A majority of the T2DM cohort (79.7%) was treated for
diabetes with an antihyperglycemic agent. These tables also summa-
rize demographic and clinical characteristics based upon highest
recorded HbA1c at any time in the study period. The majority of
individuals (91.7% of T1DM and 61.1% of T2DM)were found to have at
least one HbA1c test ≥ 7% than target over the 3-year study period.
The multinomial logistic regressions shown in Tables 2A and 2B
present the factors quantitatively associated with increased odds of
having HbA1c ≥7% and b8%, ≥8% and b9%, or ≥9% relative to HbA1c
b7% for patients with T1DM and T2DM, respectively. Among patients
with T1DM, a BMI classiﬁcation of overweight or obese was associated
with signiﬁcantly higher probability of having an HbA1c recorded
value ≥8% and b9% or ≥9%. However, while being overweight was
associated with a 30% increase in the probability of having an HbA1c
≥7% and b8% compared to having an HbA1c b7% (odds ratio [OR] =
1.301; 95% conﬁdence interval [CI] = 1.078–1.570), there was no
statistically signiﬁcant relationship between obesity (class I, II, or III)
and the probability of having an HbA1c ≥7% and b8%.
The results show that for T2DM patients, compared to normal BMI
individuals, being overweight or obese was associated with higher
odds of above-target HbA1c. Furthermore, among the T2DM cohort,
patients whowere obese (class I, II or III) had signiﬁcantly higher odds
of HbA1c above target compared to overweight individuals. For
example, overweight individuals were found to have an 18% increase
in the probability of having an HbA1c ≥7% and b8% (OR = 1.176; 95%
CI 1.132–1.222), a 15% increase in the probability of having an HbA1c
≥8% and b9% (OR = 1.148; 95% CI 1.0990–1.210), and a 16% increase
in the probability of having an HbA1c ≥9% (OR = 1.156; 95% CI 1.099–
1.216). In all cases, the odds ratios for obesity were signiﬁcantly
higher. However, there was no signiﬁcant difference in the probability
of having above target glycemic control when comparing different
classes of obesity.
Table 2A and 2B also shows the individual characteristics
associated with greater or lesser odds of having above-target
HbA1c. Among patients with T1DM, patients with diabetic retinop-
athy, diabetic nephropathy, or dyslipidemia were found to haveon – by diabetes type.
Table 1A
Demographic and clinical characteristics of patients with T1DM by glycemic control in Humedica's EHR database in years 2009–2011.
All (N = 14,028) Highest HbA1c b7%
(N = 1169)
Highest HbA1c
≥7%– b 8% (N =
2737)
Highest HbA1c
≥8%– b 9% (N =
3282)
Highest HbA1c ≥9%
(N = 6840)
P Valuea
N % N % N % N % N %
BMI b0.001
Normal 3051 21.7 319 27.3 666 24.3 650 19.8 1416 20.7
Overweight 4279 30.5 343 29.3 925 33.8 1,119 34.1 1892 27.7
Obese I 3223 23.0 265 22.7 589 21.5 775 23.6 1594 23.3
Obese II 1880 13.4 129 11.0 307 11.2 392 11.9 1052 15.4
Obese III 1595 11.4 113 9.7 250 9.1 346 10.5 886 13.0
Sex b0.001
Female 6927 49.4 532 45.5 1,294 47.3 1,595 48.6 3506 51.3
Male 7101 50.6 637 54.5 1,443 52.7 1,687 51.4 3334 48.7
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Race b0.001
African American 2279 16.2 144 12.3 281 10.3 401 12.2 1453 21.2
Asian 197 1.4 13 1.1 49 1.8 53 1.6 82 1.2
Caucasian 9051 64.5 781 66.8 1,899 69.4 2,242 68.3 4129 60.4
Other/Unknown 2501 17.8 231 19.8 508 18.6 586 17.9 1176 17.2
Region b0.001
Midwest 5612 40.0 457 39.1 1,084 39.6 1,360 41.4 2711 39.6
Northeast 1485 10.6 127 10.9 322 11.8 355 10.8 681 10.0
South 4427 31.6 372 31.8 787 28.8 907 27.6 2361 34.5
West 2500 17.8 213 18.2 543 19.8 659 20.1 1085 15.9
Other/Unknown 4 0.0 0 0.0 1 0.0 1 0.0 2 0.0
Comorbidities
Diabetic retinopathy 3642 26.0 218 18.6 709 25.9 920 28.0 1795 26.2 b0.001
Diabetic neuropathy 4416 31.5 330 28.2 756 27.6 942 28.7 2388 34.9 b0.001
Diabetic nephropathy 2902 20.7 207 17.7 520 19.0 676 20.6 1499 21.9 b0.001
Ischemic heart disease 1732 12.3 134 11.5 312 11.4 415 12.6 871 12.7 0.228
Stroke 1535 10.9 146 12.5 290 10.6 352 10.7 747 10.9 0.338
Dyslipidemia 10923 77.9 840 71.9 2,124 77.6 2,605 79.4 5354 78.3 b0.001
Hypertension 10234 73.0 824 70.5 1,961 71.6 2,388 72.8 5061 74.0 0.0207
Chronic kidney disease 3060 21.8 290 24.8 562 20.5 727 22.2 1481 21.7 0.0280
Smoking 2577 18.4 171 14.6 369 13.5 525 16.0 1512 22.1 b0.001
Anxiety 1673 11.9 129 11.0 268 9.8 321 9.8 955 14.0 b0.001
Depression 1057 7.5 92 7.9 133 4.9 222 6.8 610 8.9 b0.001
Mean Std dev Mean Std dev Mean Std dev Mean Std dev Mean Std dev P valueb
% College educated (based upon zip code) 25.17 8.84 26.03 9.02 26.14 9.14 25.67 9.10 24.40 8.48 b0.001
Charlson Score 3.12 2.19 3.16 2.33 3.02 2.23 3.08 2.19 3.17 2.14 0.011
HbA1c 9.32 2.10 6.45 0.41 7.50 0.28 8.43 0.29 10.96 1.77 b0.001
Median IQ range Median IQ range Median IQ range Median IQ range Median IQ range P valuec
Age 56 44–67 59 46–70 60 48–70 58 46–69 54 42–64 b0.001
Median and interquartile range (IQ) is presented for age since the database truncates all individuals with a year of birth of 1935 or earlier.
a P values for categorical variables are from chi-square tests of difference in proportions.
b P values for continuous variables are from t-tests of difference in means.
c P values for age is from two sample difference in median.
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chronic kidney disease had signiﬁcantly lower odds of above target
HbA1c. In the T1DM cohort, males were found to have a signiﬁcantly
lower probability of having HbA1c ≥8% and b9% or HbA1c ≥9%,
although for T2DM patients male sex was associated with a higher
probability of above target HbA1c. In both the T1and T2DM cohorts,
older age was generally associated with an increased probability of
having HbA1c ≥7% and b8% and a lower probability of HbA1c ≥9%.
Among patients with T2DM, the characteristics generally associated
with a higher likelihood of above-target HbA1c were African-Amer-
ican or Asian race (compared to Caucasian), residence in the midwest
(compared to the south), use of antihyperglycemic medications, and
the presence of comorbid diabetic retinopathy, diabetic neuropathy,
diabetic nephropathy, ischemic heart disease, hypertension, or
dyslipidemia. In contrast, for patients with T2DM, comorbid chronic
kidney disease, anxiety or depression was associated with a
signiﬁcantly lower likelihood of having above-target HbA1c.
As a test of the sensitivity of these results, HbA1c ranges were
re-classiﬁed based upon mean HbA1c over the three year studyperiod. This less-restrictive deﬁnition of above-target HbA1c resulted in
80.6% of the T1DM and 41.7% of the T2DM cohort being identiﬁed as
having above-targetHbA1c (≥7%). For patientswith T2DM, these results
are generally consistent with the main ﬁndings presented in Table 2B.
For example, when examining the probability of having a mean HbA1c
≥8% and b9% compared to having a mean HbA1c of b7%, the odds ratio
for BMI classiﬁcations of overweight and obesity ranged from 1.148 to
1.604, compared to the sensitivity analysis, where the values ranged
from 1.147 to 1.568. However, for patients with T2DM, use of mean
HbA1c was not associated with a higher probability of HbA1c N9%
among overweight patients (OR = 0.955; 95% CI 0.893–1.021).
Among patients with T1DM, use of mean HbA1c as the dependent
variable, rather than highest HBa1c value resulted in two major
changes in results. First, with the new deﬁnition of above target
glycemic control, obesity was associated with a signiﬁcantly higher
probability of having HbA1c ≥7% and b8%, compared to a mean value
of b7%. Second, when examining the probability of having a mean
HbA1c ≥9% compared to b7%, being overweight or obese I was not
signiﬁcantly associated with this higher HbA1c target.
Table 1B
Demographic and clinical characteristics of patients with T2DM by glycemic control in Humedica's EHR database in years 2009–2011.
All (N = 248,567) Highest HbA1c b7%
(N = 96,887)
Highest HbA1c
≥7%– b 8%
(N = 64,362)
Highest HbA1c
≥8%– b 9%
(N = 34,320)
Highest HbA1c ≥9%
(N = 52,998)
P valuea
N % N % N % N % N %
BMI b0.001
Normal 25,016 10.1 12,761 13.2 6157 9.6 2690 7.8 3408 6.4
Overweight 65,954 26.5 28,994 29.9 17,740 27.6 8209 23.9 11,011 20.8
Obese I 70,764 28.5 26,543 27.4 18,709 29.1 10,069 29.3 15,443 29.1
Obese II 45,529 18.3 15,506 16.0 11,640 18.1 6859 20.0 11,524 21.7
Obese III 41,304 16.6 13,083 13.5 10,116 15.7 6493 18.9 11,612 21.9
Sex b0.001
Female 126,537 50.9 52,911 54.6 32,505 50.5 16,470 48.0 24,651 46.5
Male 122,028 49.1 43,975 45.4 31,857 49.5 17,850 52.0 28,346 53.5
Unknown 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Race b0.001
African American 35,497 14.3 11,461 11.8 8661 13.5 4798 14.0 10,577 20.0
Asian 7069 2.8 2880 3.0 2158 3.4 891 2.6 1140 2.2
Caucasian 165,330 66.5 67,332 69.5 43,337 67.3 22,948 66.9 31,713 59.8
Other/Unknown 40,671 16.4 15,214 15.7 10,206 15.9 5683 16.6 9568 18.1
Region b0.001
Midwest 77,756 31.3 28,399 29.3 20,514 31.9 11,088 32.3 17,755 33.5
Northeast 19,958 8.0 9036 9.3 5221 8.1 2530 7.4 3171 6.0
South 105,303 42.4 40,244 41.5 26,986 41.9 14,747 43.0 23,326 44.0
West 45,456 18.3 19,165 19.8 11,621 18.1 5941 17.3 8729 16.5
Other/Unknown 94 0.0 43 0.0 20 0.0 14 0.0 17 0.0
Comorbidities
Diabetic Retinopathy 13,614 5.5 2617 2.7 3461 5.4 2714 7.9 4822 9.1 b0.001
Diabetic Neuropathy 32,747 13.2 9027 9.3 8319 12.9 5624 16.4 9777 18.4 b0.001
Diabetic Nephropathy 19,789 8.0 5673 5.9 5115 7.9 3442 10.0 5559 10.5 b0.001
Ischemic Heart Disease 21,926 8.8 8066 8.3 5555 8.6 3307 9.6 4998 9.4 b0.001
Stroke 24,659 9.9 10,124 10.4 6463 10.0 3431 10.0 4641 8.8 b0.001
Dyslipidemia 213,386 85.8 82,346 85.0 56,384 87.6 29,917 87.2 44,739 84.4 b0.001
Hypertension 210,252 84.6 81,295 83.9 55,376 86.0 29,524 86.0 44,057 83.1 b0.001
Chronic Kidney Disease 31,918 12.8 12,209 12.6 8360 13.0 4886 14.2 6463 12.2 b0.001
Smoking 42,053 16.9 16,405 16.9 10,014 15.6 5660 16.5 9974 18.8 b0.001
Anxiety 30,165 12.1 13,185 13.6 7307 11.4 3800 11.1 5873 11.1 b0.001
Depression 15,814 6.4 6554 6.8 3618 5.6 2075 6.0 3567 6.7 b0.001
Antiglycemic Medication Use 198,255 79.8 57,982 59.8 56,704 88.1 32,514 94.7 51,055 96.3 b0.001
Mean Std dev Mean Std dev Mean Std dev Mean Std dev Mean Std dev P valueb
% College educated (based upon zip code) 24.8 8.7 25.1 8.9 24.9 8.7 24.5 8.5 24.2 8.3 b0.001
Charlson Score 2.5 1.9 2.5 1.9 2.5 1.9 2.6 1.9 2.5 1.9 b0.001
HbA1c 7.9 1.9 6.4 0.4 7.4 0.3 8.4 0.3 10.8 1.6 b0.001
Median IQ range Median IQ range Median IQ range Median IQ range Median IQ range P valuec
Age 64 55–73 66 57–74 66 57–74 63 55–72 58 50–66 b0.001
Median and interquartile range (IQ) is presented for age since the database truncates all individuals with a year of birth of 1935 or earlier.
a P values for categorical variables are from chi-square tests of difference in proportions.
b P values for continuous variables are from t-tests of difference in means.
c P values for age is from two sample difference in median.
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This study illustrates the high obesity rates among both T1DM and
T2DM patients in the U.S. Correspondingly, the number of patients
who do not reach glycemic control is also very high. After controlling
for individual's characteristics, general health, antihyperglycemic
medication use, and comorbidities and complications, being over-
weight or obese was generally associated with an increased likelihood
of having suboptimal glycemic control in both T1DM and T2DM
cohorts. The concurrence of obesity and suboptimal glycemic control
is consistent with previous research among older adults (Martins et
al., 2012), and in a predominantly African-American population
(El-Kebbi et al., 2003).
There are potentially many factors behind the challenges in
glycemic control and obesity. Robust evidence may require high
quality long-term randomized cohort data. Databases containing
robust data are scarce, and research from existing databases has
limitations to inform the current discussion. Recently several studies
have examined socio-demographic, behavioral, and treatment-related factors behind glycemic control and generated new insights
on the potential factors of glycemic outcomes (Aikens & Piette,
2013; Feldman et al., 2014; McAdam-Marx et al., 2014; Nagrebetsky
et al., 2012).
In a prospective randomized trial where electronic sensor was
used to measure prescription adherence, Nagrebetsky et al. (2012)
studied the effects of medication adherence on glycemic outcomes in
T2DM patients. The study found older age, weight loss and better
adherence (≥80%), among other factors, predicted lower HbA1c at
1 year. Further investigation found the better glycemic controls in the
older patients are not explained by better adherence, but may be
partly related to lower BMI. Grandy, Fox, and Hardy (2013) conﬁrmed
that adherence improves with weight loss in T2DM population.
McAdam-Marx et al. (2014) compared effects of weight loss
and adherence on glycemic control in a health plan population.
The study found both weight loss and adherence were associated
with glycemic control in T2DM, but weight loss was a stronger
predictor than adherence of glycemic control. The literature suggests
that there is an indirect effect of weight gain; patients who gain
Table 2A
Multinomial logistic regression – factors associated with alternative HbA1c ranges – type 1 diabetes.
Highest HbA1c ≥7%– b 8%⁎ Highest HbA1c ≥8%– b 9%⁎ Highest HbA1c ≥9%⁎
Odds
ratio
95% Conﬁdence
interval
Odds
ratio
95% Conﬁdence
interval
Odds
ratio
95% Conﬁdence
interval
Lower Upper Lower Upper Lower Upper
AgeA
Age 45–54 1.231 0.977 1.551 0.971 0.775 1.217 0.788 0.639 0.972
Age 55–64 1.394 1.108 1.753 1.002 0.801 1.253 0.650 0.527 0.802
Age 65–73 1.291 1.006 1.656 0.857 0.672 1.093 0.405 0.322 0.509
Age 74 or Older 1.106 0.855 1.431 0.770 0.599 0.989 0.270 0.212 0.343
SexB
Male 0.868 0.751 1.003 0.809 0.703 0.932 0.768 0.674 0.876
RaceC
African American 0.819 0.648 1.035 0.902 0.721 1.129 1.677 1.373 2.048
Asian 1.562 0.826 2.952 1.351 0.719 2.538 1.594 0.862 2.946
Race Other/Unknown 0.888 0.738 1.069 0.860 0.717 1.031 1.021 0.861 1.209
RegionD
Midwest 1.109 0.931 1.323 1.205 1.015 1.430 0.958 0.819 1.122
Northeast 1.115 0.849 1.465 1.119 0.853 1.468 1.174 0.909 1.517
West 1.155 0.930 1.435 1.241 1.005 1.532 0.908 0.743 1.108
% College educated 0.997 0.988 1.006 0.993 0.985 1.002 0.986 0.978 0.994
Charlson Comorbidity Index 0.960 0.919 1.003 0.956 0.915 0.998 0.961 0.921 1.002
Diabetic retinopathy 1.526 1.270 1.833 1.706 1.427 2.040 1.514 1.277 1.796
Diabetic neuropathy 0.983 0.821 1.175 0.975 0.820 1.159 1.342 1.142 1.577
Diabetic nephropathy 1.324 1.054 1.663 1.339 1.079 1.663 1.417 1.157 1.735
Ischemic heart disease 1.103 0.865 1.406 1.206 0.955 1.525 1.239 0.991 1.548
Stroke 0.952 0.748 1.212 0.954 0.755 1.205 1.036 0.833 1.290
Dyslipidemia 1.332 1.118 1.588 1.511 1.268 1.802 1.504 1.277 1.770
Chronic kidney disease 0.668 0.541 0.824 0.726 0.594 0.889 0.664 0.550 0.800
Hypertension 0.958 0.788 1.163 0.978 0.806 1.186 1.142 0.952 1.368
Smoking 1.001 0.814 1.229 1.182 0.971 1.438 1.598 1.333 1.915
Anxiety 1.002 0.788 1.273 0.896 0.710 1.131 1.081 0.878 1.332
Depression 0.612 0.456 0.821 0.804 0.614 1.052 0.904 0.709 1.154
WeightE
Overweight 1.301 1.078 1.570 1.612 1.337 1.943 1.260 1.057 1.502
Obese I 1.095 0.888 1.348 1.454 1.185 1.785 1.347 1.111 1.634
Obese II 1.133 0.876 1.467 1.454 1.128 1.875 1.778 1.404 2.251
Obese III 1.119 0.847 1.479 1.468 1.123 1.919 1.622 1.264 2.082
Hosmer–Lemeshow Goodness of Fit P = 0.3582 P = 0.7378 P = 0.8940
Results from multinomial logistic regression.
⁎ Reference category HbA1c b7%.
A Reference category age b 45.
B Reference category females.
C Reference category Caucasian.
D Reference category south or unknown region.
E Reference category normal or underweight (BMI b 25).
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the present study has only number of treatments, but no information
on medication adherence.
However, the results are inconsistent with an examination of the
NHANES data which found that mean HbA1c was highest among
individuals with normal BMI (Nguyen et al., 2011). Furthermore,
among patients with T2DM, obesity (class I, II, or III) was associated
with a signiﬁcant higher probability of having HbA1c ≥7% and b8%,
≥8% and b9%, or ≥9% relative to overweight individuals. This ﬁnding
suggests that weight changes within the obesity categories may not
be as beneﬁcial in maintaining glycemic control compared to moving
from obese to overweight or normal BMI.
Research from a prospective study over 12 years found that weight
loss among overweight patients with T2DMwas associatedwith a 25%
reduction in mortality, as well as a 28% reduction in cardiovascular
disease (Williamson et al., 2000). In contrast, however, the Look
AHEAD clinical trial found that weight loss among overweight or
obese individuals with T2DM did not reduce the rate of cardiovascular
events over 13.5 years (Look AHEAD Research Group, 2013). The
difference in these results may be due to the difference in study
design, with patients randomized in clinical trials. Furthermore, there
were signiﬁcant differences in inclusion and exclusion criteria
between the two studies, with the prospective study focusing onthose age 41–64 with a BMI of at least 27 who had complete data on
weight, height, smoking, alcohol use, education, physical activity, and
race (Williamson et al., 2000) and the clinical trial study requiring
patients to be age 45–75 with a BMI ≥ 25, HbA1c ≤ 11%, systolic blood
pressure b 160 mmHg, diastolic blood pressure b 100 mmHg, tri-
glyceride level b 100 mg per deciliter, and the ability to complete a
valid maximal exercise test (Look AHEAD Research Group, 2013).
Research has also demonstrated the reduction in microvascular
complications (Svensson, Eriksson, & Dahlquist, 2004; UK Prospective
Diabetes Study (UKPDS) Group, 1998) and medical care charges
(Gilmer, O’Connor, Manning, & Rush, 1997) associated with improved
glycemic control among patients with diabetes as well as a reduction
in cardiovascular risk among patients with T1DM (Ferranti et al.,
2014). Taken together, the ﬁndings of this research are consistent
with previous research which has found signiﬁcant health and
economic beneﬁts associated with weight loss among patients with
diabetes who are overweight or obese.
Consistent with guidelines that suggest a target of b8% may be
appropriate for patients with a limited life expectancy (American
Diabetes Association, 2015) and from results from an observational
study which suggest that a target HbA1c of 8 to 8.9% may be
appropriate for the elderly (Yau et al., 2012), the results of this
analysis generally found that as age increased, patients were more
Table 2B
Multinomial logistic regression – factors associated with alternative HbA1c ranges – type 2 diabetes.
HbA1c ≥7%– b 8%⁎ HbA1c ≥8%– b 9%⁎ HbA1c ≥9%⁎
Odds
ratio
95% Conﬁdence
interval
Odds
ratio
95% Conﬁdence
interval
Odds
ratio
95% Conﬁdence
interval
Lower Upper Lower Upper Lower Upper
AgeA
Age 45–54 1.245 1.179 1.315 1.099 1.032 1.171 0.849 0.808 0.892
Age 55–64 1.225 1.163 1.290 0.965 0.909 1.025 0.536 0.512 0.562
Age 65–73 1.215 1.153 1.281 0.792 0.744 0.842 0.291 0.277 0.307
Age 74 or Older 1.157 1.096 1.222 0.654 0.613 0.698 0.173 0.164 0.183
SexB
Male 1.180 1.154 1.206 1.313 1.278 1.350 1.412 1.376 1.448
RaceC
African American 1.127 1.090 1.165 1.083 1.039 1.128 1.566 1.511 1.623
Asian 1.373 1.288 1.464 1.155 1.059 1.259 1.034 0.951 1.124
Race Other/Unknown 1.046 1.015 1.079 1.097 1.056 1.140 1.272 1.229 1.317
RegionD
Midwest 1.048 1.021 1.075 1.021 0.989 1.054 1.033 1.003 1.064
Northeast 1.040 0.995 1.088 0.994 0.937 1.054 0.911 0.860 0.964
West 0.884 0.857 0.912 0.813 0.781 0.846 0.790 0.761 0.820
% College educated 1.000 0.999 1.002 0.997 0.995 0.999 0.995 0.993 0.997
Charlson Comorbidity Index 0.984 0.977 0.991 0.996 0.987 1.005 0.999 0.990 1.008
Diabetic retinopathy 1.667 1.577 1.762 2.363 2.221 2.513 2.835 2.676 3.003
Diabetic neuropathy 1.239 1.195 1.284 1.526 1.463 1.592 1.927 1.853 2.005
Diabetic nephropathy 1.262 1.203 1.325 1.469 1.388 1.555 1.708 1.620 1.802
Ischemic heart disease 1.074 1.032 1.118 1.192 1.135 1.253 1.342 1.281 1.406
Stroke 1.006 0.969 1.045 1.033 0.985 1.084 1.103 1.053 1.155
Dyslipidemia 1.131 1.096 1.168 1.100 1.057 1.145 0.990 0.955 1.025
Chronic kidney disease 0.933 0.899 0.967 1.000 0.956 1.047 0.952 0.911 0.995
Hypertension 1.037 1.005 1.070 1.048 1.007 1.090 1.009 0.974 1.045
Smoking 0.918 0.891 0.945 0.927 0.893 0.961 1.023 0.990 1.057
Anxiety 0.886 0.857 0.915 0.845 0.810 0.882 0.774 0.745 0.805
Depression 0.877 0.838 0.917 0.887 0.838 0.939 0.906 0.862 0.953
Antiglycemic medication use 4.741 4.612 4.873 10.873 10.347 11.426 15.108 14.394 15.857
WeightE
Overweight 1.176 1.132 1.222 1.148 1.090 1.210 1.156 1.099 1.216
Obese I 1.304 1.254 1.355 1.407 1.335 1.482 1.471 1.400 1.547
Obese II 1.356 1.300 1.415 1.530 1.446 1.618 1.608 1.525 1.695
Obese III 1.370 1.310 1.433 1.604 1.514 1.700 1.622 1.537 1.712
Hosmer–Lemeshow Goodness of Fit P b 0.0001 P b 0.0001 P b 0.0001
Results from multinomial logistic regression.
⁎ Reference category HbA1c b7%.
A Reference category age b 45.
B Reference category females.
C Reference category Caucasian.
D Reference category south or unknown region.
E Reference category normal or underweight (BMI b 25).
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signiﬁcantly less likely to have an HbA1c N9%. These results suggest
that physicians may be less restrictive regarding HbA1c among the
elderly. Among patients with T2DM, Caucasians were found to be
more likely to achieve the HbA1c target of b7%. This ﬁnding is
consistent with previous research which has examined racial
disparities in HbA1c among patients with T2DM (Egede et al., 2011;
Kirk et al., 2006).
In this study, males with T1DM were found to be signiﬁcantly less
likely to have an above-target HbA1c while males with T2DM were
found to be signiﬁcantly more likely to have above-target HbA1c. This
ﬁnding is consistent with prior research which has found improved
glycemic control among females with T2DM (Kirk et al., 2011), as well
as with research that has found higher HbA1c levels among women
with T1DM (Göbl et al., 2012). Complications of diabetes (diabetic
retinopathy, diabetic neuropathy, and diabetic nephropathy) were
associated with a higher likelihood of suboptimal glycemic control in
both cohorts. This ﬁnding is in concert with previous research which
has examined the role of comorbidities in general (Egede et al., 2011),
as well as with studies which focused on the relationship between
HbA1c and the risk of the development or progression of retinopathy
(Diabetes Control and Complications Trial Research Group, 1995),polyneuropathy (El-Salem, Ammari, Khader, & Dhaimat, 2009), or
nephropathy (Sabanayagam et al., 2009). Among patients with both
T1DM and T2DM, comorbid CKD was associated with a signiﬁcant
reduction in the odds of having above target HbA1c. Such results may
be due to the increased physician monitoring necessitated by worse
general health.
Among individuals with T2DM, residents of western states
(compared to southern states) were less likely to have suboptimal
glycemic control, a result that is consistent with previous research on
regional variations in glycemia (Swanson, Potter, Kongable, & Cook,
2011) and obesity rates (Centers for Disease Control and Prevention,
2014a). In contrast, among the T2DM cohort, people living in the
midwest were more likely to have suboptimal glycemic control, a
ﬁnding which is consistent with national statistics indicating the
midwest to be the US region with the lowest rate of healthy
(self-described) patients with diabetes (Kirtland, Zack, & Caspersen,
2012) and one of the highest rate of obesity (Centers for Disease
Control and Prevention, 2014a). Individuals with T2DM and comorbid
anxiety or depression were signiﬁcantly less likely to have suboptimal
glycemic control; these results are inconsistent with previous
research that showed that depression (Papelbaum et al., 2011) and
anxiety (Anderson et al., 2002) are associated with worse glycemic
219J.P. Bae et al. / Journal of Diabetes and Its Complications 30 (2016) 212–220control. It may be however, that in this insured population, these
patients visit their physician more frequently and hence have the
opportunity for more intensive monitoring of their HbA1c. Finally,
patients with T2DM who were not taking antihyperglycemic drugs
were also generally less likely to have suboptimal glycemic control, a
ﬁnding which suggests that the lack of antihyperglycemic medication
use may indicate that the diabetes is less severe relative to individuals
who are treated pharmacologically. However, it should be noted that
22.7% of the individuals with T2DM who were not treated with
antihyperglycemic medication had suboptimal glycemic control.
The results of this study must be interpreted within the limits of
the study design. First, these analyses were based on retrospective,
electronic medical data from the physician practice setting, and may
therefore be limited in their generalizability. For example, the use of
diagnostic codes is not as rigorous as formal assessments and may
underrepresent certain conditions. Furthermore, as mentioned pre-
viously the database analyzed contains no information on medication
adherence, the duration or severity of disease or on various individual
behaviors, such as diet and exercise, which may inﬂuence outcomes.
The analyses may also not have captured all variables that may
potentially impact glycemic control, such as blood pressure medica-
tion or lipid use, foot and eye examinations, and number of physician
visits. In addition, the cross-sectional study design focused on the
association between BMI classiﬁcations and glycemic control and was
unable to allow for a direct examination of causation. Finally, the
analyses presented statistically signiﬁcant differences, some of which
resulted from a large sample size. Therefore, an observed statistically
signiﬁcant difference does not necessarily indicate a clinically
signiﬁcant difference.
In conclusion, this real-world retrospective investigation of
patients identiﬁed with T1DM or T2DM revealed a relationship
between BMI and a greater likelihood of having suboptimal glycemic
control. This ﬁnding quantiﬁes the association between BMI and
glycemic control and highlights the potential importance of an
individual's characteristics such as age, race, and comorbidities for
glycemic control. Results show that for patients with T1DM, patients
who are overweight or obese are more likely to have an HbA1c value
≥8% and b9% or ≥9% and that overweight patients are more likely to
have an HbA1c value N7% and b8%, compared to a value of b7%.
Among patients with T2DM, overweight and obese individuals are
more likely than those in normal weight range to have an HbA1c value
≥7% and b8%, ≥8% and N9%, or ≥9%, compared to a value of b7%.
However, while obese individuals were more likely than overweight
individuals with T2DM to have poor glycemic control, there was no
statistical difference in the probability of having above target glycemic
control when comparing alternative classes of obesity.References
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